The Promise of Low Dose Naltrexone Therapy (häftad)
Fler böcker inom
Häftad (Paperback / softback)
Antal sidor
McFarland & Co Inc
Agrawal, Yash Pal
21 photographs
224 x 150 x 18 mm
340 g
Antal komponenter
423:B&W 6 x 9 in or 229 x 152 mm Perfect Bound on White w/Matte Lam
The Promise of Low Dose Naltrexone Therapy (häftad)

The Promise of Low Dose Naltrexone Therapy

Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders

Häftad Engelska, 2008-11-21
Skickas inom 10-15 vardagar.
Fri frakt inom Sverige för privatpersoner.
Finns även som
Visa alla 1 format & utgåvor
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis and autism. While ongoing clinical trials are evaluating the use of LDN in treating fibromyalgia and HIV/AIDS, it has been shown to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in available clinical and scientific research, this book describes the history of naltrexone, including its potential therapeutic uses, its effects on the immune system, and its pharmacological properties. Aiming to acquaint readers with the potential therapeutic benefits of LDN, the book also includes practical chapters for those interested in its use, focusing on such topics as how the drug is administered, information on fillers and compounding pharmacies, lists of doctors who prescribe LDN, and available patient resources. It also features interviews with LDN patients and several of the country's top LDN researchers, who describe the importance of LDN in terms of its ability to provide relief from pain, halt disease progression, and facilitate the body's ability to heal. Finally, the work includes a useful glossary and an appendix listing important clinical trials completed to date, complete with researcher contact information and a summary of the trial outcomes.
Visa hela texten

Passar bra ihop

  1. The Promise of Low Dose Naltrexone Therapy
  2. +
  3. The Amphetamine Debate

De som köpt den här boken har ofta också köpt The Amphetamine Debate av Elaine A Moore (häftad).

Köp båda 2 för 638 kr


Har du läst boken? Sätt ditt betyg »

Fler böcker av författarna

Recensioner i media

"fascinating...very well a convincing and compelling medical textbook"

Övrig information

Elaine A. Moore has worked in hospital laboratories for more than 30 years, primarily in immunohematology and toxicology. She is the author of Hepatitis (2006), Encyclopedia of Sexually Transmitted Diseases (2005), Encyclopedia of Alzheimer's Disease; With Directories of Research, Treatment and Care Facilities (2003), Autoimmune Diseases and Their Environmental Triggers (2002) and Graves' Disease (2001). She lives in Sedalia, Colorado. Samantha Wilkinson lives in Edmonds, Washington.


table of contents

acknowledgments   vi

Foreword by Yash Pal Agrawal, M.D., Ph.D.   1

Preface   5

Introduction   7

1. the war on drugs—a history of naltrexone   11

2. LDN in Autoimmune Diseases   29

3. LDN in Multiple Sclerosis   45

4. LDN in Neurodegenerative Disorders   61

5. LDN in Cancer   78

6. LDN in Autism Spectrum Disorders   95

7. LDN in Wound Healing and Infections   102

8. The Immune System and LDN in HIV/AIDS   108

9. The LDN Experience: A Patient’s Guide to LDN   126

10. The Potential Benefits and Future of LDN   148

chapter notes   159

Glossary   167

Appendix: Clinical Trials of LDN and Related Compounds   179

Resources   189

Index   209